Literature DB >> 600762

[Benign breast diseases: hormonal studies in 125 cases (author's transl)].

P Mauvais-Jarvis, F Kuttenn, I Mowszowicz, R Sitruk-Ware.   

Abstract

The results of exploration of the corpus luteum in 125 patients with benign breast disease are analysed. In 109 patients, plasma oestradiol and progesterone were measured at various times during the hyperthermic phase of the menstrual cycle. The results obtained were compared with those obtained in normal women explored during the same phase of the cycle. The average daily values for plasma progesterone obtained in this group of 109 patients was significantly lower than that found in the normal women, whilst there was no change in oestradiol levels. In addition, 16 patients were studied daily throughout the period of hyperthermia. In 8 cases, there the hyperoestrogenism, with or without progesterone insifficiency of the corpus luteum. In all, secretory imbalance of the corpus luteum with a tendency to relative or absolute hyperoestrogenism was a constant finding in women with benign breast disease.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 600762

Source DB:  PubMed          Journal:  Nouv Presse Med        ISSN: 0301-1518


  4 in total

1.  Nimesulide in the treatment of mastalgia.

Authors:  G Gabbrielli; P Binazzi; I Scaricabarozzi; G B Massi
Journal:  Drugs       Date:  1993       Impact factor: 9.546

2.  Growth regulation of two rat adenocarcinoma cell lines by dexamethasone and progesterone.

Authors:  E Joly; F Vignon; H Rochefort
Journal:  Breast Cancer Res Treat       Date:  1981       Impact factor: 4.872

3.  Dehydroepiandrosterone sulphate plasma levels in normal women and patients with benign breast disease.

Authors:  E Parlati; I Liberale; P Morelli; P Serva; A Travaglini; A Piccione; E Menini; S Dell'Acqua
Journal:  J Endocrinol Invest       Date:  1992-02       Impact factor: 4.256

4.  Hormonal profile in benign breast disease. Endocrine status of cyclical mastalgia patients.

Authors:  E Parlati; A Travaglini; I Liberale; E Menini; S Dell'Acqua
Journal:  J Endocrinol Invest       Date:  1988-10       Impact factor: 4.256

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.